(Atorvastatin + ezetimibe) is under clinical development by Addpharma and currently in Phase I for Hyperlipidemia. According to GlobalData, Phase I drugs for Hyperlipidemia have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Atorvastatin + ezetimibe)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Atorvastatin + ezetimibe) overview

Atorvastation in combination with ezetimibe is under development for the treatment of primary hypercholesterolemia and hyperlipidemia. It is an incrementally modified drug (IMD). It is administered through oral route. Atorvastatin targets HMG-CoA reductase and ezetimibe targets Niemann-Pick C1-like protein 1.

Addpharma overview

Addpharma is a specialized pharmaceutical company that develops medicinal novel drugs including complexes, release controlling agents, and absorption improving agents. Addpharma is headquartered in Yongin, South Korea.

For a complete picture of (Atorvastatin + ezetimibe)’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.